Found 10 articles for: "Roflumilas"
Practical Algorithm Guiding Seborrheic Dermatitis Treatment in Adults and Adolescents: New Evidence and Consensus Expert Opinion
November 2026 | Volume 25 | Issue 11 | Original Article | 1019 | Copyright © November 2026
Background: Seborrheic dermatitis (SD) is a common, chronic inflammatory skin disease characterized by greasy, scaly plaques on the scalp or body, often with pruritus and impaired ...
Read MoreBiologics and Small-Molecule Inhibitors for the Treatment of Nummular Eczema: A Systematic Review
October 2026 | Volume 25 | Issue 10 | Original Article | 919 | Copyright © October 2026
Background: Nummular eczema (NE) is a chronic, pruritic dermatitis with substantial patient burden and no FDA-approved therapies. Emerging data suggest that biologics and small-m...
Read MoreVitiligo Successfully Treated With Roflumilast Cream 0.3%
July 2026 | Volume 25 | Issue 7 | Case Reports | 662 | Copyright © July 2026
Vitiligo is an autoimmune cutaneous depigmenting disorder that can have significant psychological impacts on affected patients, posing a burden to daily life, which can be even more apparent in p...
Read MoreAdvanced Topical Nonsteroidal Therapies for Atopic Dermatitis: Consensus Statements from an Expert Panel
March 2026 | Volume 25 | Issue 3 | Original Article | 221 | Copyright © March 2026
Background: Advanced topical nonsteroidal therapies are expanding options for atopic dermatitis (AD) by providing targeted anti-inflammatory control without many limitations of l...
Read MoreVisualization of Topical Roflumilast Versus Vehicle using Line-Field Optical Coherence Tomography in Healthy Skin
November 2025 | Volume 24 | Issue 11 | Original Article | 1126 | Copyright © November 2025
Background: Roflumilast is a topical phosphodiesterase-4 inhibitor FDA-approved for treating plaque psoriasis and atopic dermatitis. Line-field confocal optical coherence tomogra...
Read MorePDE4 Inhibitors: Bridging Molecular Insights With Clinical Impact
June 2025 | Volume 24 | Issue 6 | Original Article | 631 | Copyright © June 2025
Read MoreNeed for Speed: Topical Roflumilast for Rapid Control of Seborrheic Dermatitis Flares
June 2025 | Volume 24 | Issue 6 | Case Reports | 634 | Copyright © June 2025
Seborrheic dermatitis is a common chronic inflammatory skin condition historically treated with topical antifungals and anti-inflammatory agents. While topical corticosteroids are frequently used...
Read MoreAssessment of the Vehicle for Roflumilast Cream Compared to a Ceramide-Containing Moisturizing Cream in Mild Eczema
October 2024 | Volume 23 | Issue 10 | Original Article | 834 | Copyright © October 2024
Read MorePolymorphous Light Eruptions Treated With Roflumilast 0.3% Cream: A Case Report
August 2024 | Volume 23 | Issue 8 | Case Reports | 686 | Copyright © August 2024
The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Patients With Atopic Dermatitis: Randomized, Double-Blind, Phase 2 Proof of Concept Study
February 2023 | Volume 22 | Issue 2 | Original Article | 139 | Copyright © February 2023
Background: Patients with atopic dermatitis (AD) need safe and effective topical treatments.
Objective: To assess safety and efficacy of roflumilast cream in pa...
Read More© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
